Clinical Trial Update: Camrelizumab Combined With Endostar for First-line Treatment in Subjects With Advanced Squamous NSCLC [Phase 2]

View source ↗

Summary

Phase 2 trial update evaluating camrelizumab combined with Endostar as first-line treatment for advanced squamous non-small cell lung cancer (NSCLC).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Camrelizumab (camrelizumab)
• Endostar (recombinant human endostatin)

Snippet

Sponsor: Peking University Cancer Hospital & Institute | Conditions: Non-small Cell Lung Cancer | Phase 2 | Status: UNKNOWN